Chemistry:Ipatasertib
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | PO |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C24H32ClN5O2 |
| Molar mass | 458.00 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ipatasertib (RG7440) is an experimental cancer drug in development by Roche. It is a small molecule inhibitor of AKT, which is a key component of the PI3K/AKT pathway. Ipatasertib was discovered by Genentech in collaboration with Array Biopharma and is currently in phase II trials for treatment of breast cancer.[1]
In vitro, ipatasertib showed activity against all three isoforms of Akt.[2]
References
- ↑ Clinical trial number NCT02301988 for "A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer" at ClinicalTrials.gov
- ↑ "Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models". Clinical Cancer Research 19 (7): 1760–72. April 2013. doi:10.1158/1078-0432.CCR-12-3072. PMID 23287563.
 |  |
